Lawson DO, Eraso M, Mbuagbaw L, et al. - Researchers intended to explore the efficacy and safety of dose reduction of tumour necrosis factor inhibitor (TNFi) therapy in the treatment of axial spondyloarthritis (axSpA), compared with usual care. This study enrolled six randomized trials including a total of 747 individuals (442 AS and 305 nr‐axSpA). This analysis carried out to search CENTRAL, Embase, MEDLINE and trial registries. They screened, extracted data, and evaluated risk of bias in duplicate.  A random‐effects models were applied to pool the data; subgroup analyses were conducted for type of TNFi, prior TNFi exposure and follow‐up duration. It was demonstrated that individuals with axSpA may experience little to no clinical advantage from reduction of TNFi therapy. Maintaining the standard dose probably increases the sustained impact on disease activity and supports to prevent disease flare.